OSE Immunotherapeutics is excited to announce a funding milestone of US$1,300,000 that will significantly accelerate its groundbreaking work in immuno-oncology and immuno-inflammation. As a biotechnology leader dedicated to developing first-in-class assets, the company is leveraging this new capital injection to bolster the clinical and preclinical advancement of its diverse pipeline. Among its flagship programs is Tedopi®, a therapeutic cancer vaccine now progressing into Registration Phase 3 trials for 2nd-line NSCLC in HLA-A2+ patients with secondary resistance, while ongoing Phase 2 trials—sponsored by leading onco groups—continue to explore its use in combination settings for solid tumors.
In parallel, promising results from Lusvertikimab, an IL-7R antagonist mAb, in ulcerative colitis and in preclinical research targeting ALL further underscore the potential of OSE’s portfolio. The innovative anti-PD1 candidate, OSE-279, has shown encouraging results in Phase 1/2 studies in solid tumors, while FR-104/VEL-101, an anti-CD28 mAb developed in collaboration with Veloxis, has advanced with successful Phase 1 data in the US and ongoing Phase 1/2 trials in renal transplant settings. Additionally, the company is progressing an anti-SIRPα mAb—developed with Boehringer Ingelheim—which has demonstrated promising Phase 1 results and is poised for Phase 2 trials at the end of 2024, and ABBV-230, a ChemR23 agonist mAb developed with AbbVie for chronic inflammation.
This funding will also strengthen research across OSE’s four proprietary drug discovery platforms, including its Pro-resolutive mAb, Myeloid Checkpoint, BiCKI®, and mRNA Therapeutic platforms. The new capital represents a commitment to accelerating the development of innovative therapies that address challenging unmet medical needs.
